Immutep Ltd Reinstated to ASX Quotation
Key points
- Suspension of trading in Immutep Ltd (IMM) securities lifted
- Announcement regarding TACTI-004 Phase III trial interim futility analysis
- Lead candidate eftilagimod alfa evaluated in KEYNOTE-F91 trial
Full summary
Immutep Ltd (IMM) has been reinstated to ASX quotation following the release of an announcement regarding the outcome of the pre-specified interim futility analysis for the TACTI-004 (KEYNOTE-F91) Phase III trial evaluating its lead candidate, eftilagimod alfa. The suspension of trading in IMM securities has been lifted immediately after the release of this announcement. The TACTI-004 (KEYNOTE-F91) Phase III trial is evaluating eftilagimod alfa, Immutep's lead candidate, in combination with pembrolizumab. The pre-specified interim futility analysis has been conducted, and the outcome of this analysis has been announced by the company. This reinstatement to quotation allows trading in IMM securities to resume on the ASX.
Summary generated by a large language model. Please interpret with care.